Alphamab Oncology Unveils Promising Clinical Data on Anti-HER2 Bispecific ADC Subcutaneous Co-formulation JSKN033 at SITC...

Daiichi Sankyo links up with Korea’s Alteogen on subcutaneous Enhertu in $300M licensing deal

$20 Billion Market Breakthrough: IPA Pioneers High-Impact Antibody Development for Next-Generation ADC Cancer Therapies

GSK Builds Case for Blenrep with Multiple Myeloma OS Data That Bests J&J’s Darzalex

Mabwell’s Novel Nectin-4 Targeting ADC 9MW2821 Approved for 2 Clinical Trials by CDE of NMPA

Datopotamab Deruxtecan New BLA Submitted for Accelerated Approval in the U.S. for Patients with Previously...

ENHERTU Receives Prestigious 2024 Prix Galien USA Award for Best Biotechnology Product

AstraZeneca, Daiichi withdraw lung cancer approval application for Enhertu follow-up and try again